Euglycemic diabetic ketoacidosis: A missed diagnosis.

World J Diabetes

Department of Critical Care Medicine, NMC Specialty Hospital, Dubai 7832, United Arab Emirates.

Published: May 2021

Euglycemic diabetic ketoacidosis (DKA) is an acute life-threatening metabolic emergency characterized by ketoacidosis and relatively lower blood glucose (less than 11 mmol/L). The absence of hyperglycemia is a conundrum for physicians in the emergency department and intensive care units; it may delay diagnosis and treatment causing worse outcomes. Euglycemic DKA is an uncommon diagnosis but can occur in patients with type 1 or type 2 diabetes mellitus. With the addition of sodium/ glucose cotransporter-2 inhibitors in diabetes mellitus management, euglycemic DKA incidence has increased. The other causes of euglycemic DKA include pregnancy, fasting, bariatric surgery, gastroparesis, insulin pump failure, cocaine intoxication, chronic liver disease and glycogen storage disease. The pathophysiology of euglycemic DKA involves a relative or absolute carbohydrate deficit, milder degree of insulin deficiency or resistance and increased glucagon/insulin ratio. Euglycemic DKA is a diagnosis of exclusion and should be considered in the differential diagnosis of a sick patient with a history of diabetes mellitus despite lower blood glucose or absent urine ketones. The diagnostic workup includes arterial blood gas for metabolic acidosis, serum ketones and exclusion of other causes of high anion gap metabolic acidosis. Euglycemic DKA treatment is on the same principles as for DKA with correction of dehydration, electrolytes deficit and insulin replacement. The dextrose-containing fluids should accompany intravenous insulin to correct metabolic acidosis, ketonemia and to avoid hypoglycemia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107974PMC
http://dx.doi.org/10.4239/wjd.v12.i5.514DOI Listing

Publication Analysis

Top Keywords

euglycemic dka
24
diabetes mellitus
12
metabolic acidosis
12
euglycemic
8
euglycemic diabetic
8
diabetic ketoacidosis
8
dka
8
lower blood
8
blood glucose
8
diagnosis
5

Similar Publications

Classic diabetic ketoacidosis and the euglycemic variant: Something old, something new.

Cleve Clin J Med

January 2025

Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.

Diabetic ketoacidosis (DKA) was historically considered a condition typical of type 1 diabetes. However, patients with type 2 diabetes may present with DKA, usually with higher blood glucose levels and milder ketoacidosis. With the increased use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, the variant euglycemic DKA has been described.

View Article and Find Full Text PDF

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors.

Pharmaceuticals (Basel)

November 2024

Department of Endocrinology and Metabolism, Faculty of Medicine, Recep Tayyip Erdogan University, Rize 53100, Türkiye.

: The antidiabetic effect of SGLT2 inhibitors (SGLT2-is) is based on their ability to increase glucose excretion through urine by inhibiting the kidney-resident SGLT2 protein. Euglycemic diabetic ketoacidosis (EuDKA) is an uncommon but potentially life-threatening adverse effect of these medications, which are notable for their antidiabetic, cardiovascular, and renal protective properties. This study aimed to clarify the impact of SGLT2-is on demographic, clinical, and biochemical characteristics in patients with DKA.

View Article and Find Full Text PDF

Background: The development of minimally invasive continuous glucose monitoring systems (CGMs) has transformed diabetes management. CGMs have shown clinical significance by improving time in the euglycemic range, decreasing rates of hypoglycemia, and improving HbA1c. In Rwanda, CGMs are currently not in routine use, and no clinical studies of CGM use were identified in the literature.

View Article and Find Full Text PDF
Article Synopsis
  • * A case study details a 60-year-old man with type 2 diabetes and metastatic melanoma who developed euglycemic diabetic ketoacidosis (DKA) during and after brain surgery, despite having normal blood sugar levels.
  • * Effective management of euglycemic DKA involves recognizing its subtle symptoms, administering intravenous insulin with dextrose, correcting metabolic issues, and stopping SGLT2i use, especially in surgical settings.
View Article and Find Full Text PDF

Diabetic ketoacidosis (DKA) is a life-threatening complication of type 1 and type 2 diabetes resulting from an absolute or relative insulin deficiency. It can occur in patients of all ages and can be the initial presentation of diabetes, especially in young children. Polyuria and polydipsia are the most common symptoms, followed by nausea, vomiting, abdominal pain, weight loss, severe fatigue, dyspnea, and preceding febrile illness.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!